Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
Brie Chun(Providence Portland Medical Center), David B. Page(Providence Portland Medical Center)
Cited by 18
Related Papers
Current Landscape of Immunotherapy in Breast Cancer
|JAMA Oncology|2019|409
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
|npj Breast Cancer|2019|86